Peer-reviewed veterinary case report
Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.
- Journal:
- Bioorganic & medicinal chemistry letters
- Year:
- 2007
- Authors:
- Shi, Qing et al.
- Affiliation:
- Eli Lilly and Company · United States
- Species:
- rodent
Abstract
A series of potent amide linked PPARgamma/delta dual agonists (1a) has been discovered through rational design. In the ZDF rat model of type 2 diabetes, compound (R)-3-[4-(3-{1-[(5-chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-5-fluoro-phenoxy)-2-ethyl-phenyl]-propionic acid (42) from this series has demonstrated glucose lowering efficacy comparable to the marketed PPARgamma agonist rosiglitazone with less weight gain.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/18029178/